TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5 Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery or local ablative therapy.
Epistemonikos ID: 8b74f5c43e567db843f7980836ab22902d177fb9
First added on: May 11, 2024